Core Insights - Nanobiotix provided an operational update and financial results for the year ended December 31, 2025, highlighting advancements in its clinical programs and financial position [1][6]. Operational Highlights - The global development program for JNJ-1900 (NBTXR3) is progressing as planned, targeting significant markets in oncology, particularly in head and neck and lung cancers [3]. - Clinical results across various tumor types, including esophageal, pancreatic, melanoma, head and neck, and lung cancers, support the broad potential of JNJ-1900 [3]. - The company strengthened its financial position through a non-dilutive royalty financing of up to €71 million and an amendment to the licensing agreement for JNJ-1900 [3]. - Cash runway extended into early 2028 with €52.8 million in cash and cash equivalents as of December 31, 2025 [3][12]. Financial Results - Revenues for the year ended December 31, 2025, were €32.6 million, a significant increase from a negative €7.2 million in 2024, primarily due to a one-off positive revenue recognition impact [8]. - Research and Development (R&D) expenses decreased by 43% to €23.1 million, reflecting the removal of funding obligations for the NANORAY-312 study [9]. - Selling, General and Administrative (SG&A) expenses were €20.4 million, a slight decrease from €20.5 million in 2024 [10]. - The net loss attributable to shareholders was €24.0 million, or €0.50 per share, a 65% decrease from €68.1 million, or €1.44 per share, in 2024 [11]. Future Outlook - The company anticipates that its cash and cash equivalents will support operations into early 2028, contingent on receiving the remaining $21 million from HealthCare Royalty [13]. - Nanobiotix is positioned for continued growth with upcoming clinical data readouts expected in 2026 from various studies [3][5].

Core Viewpoint - The E.W. Scripps Company has successfully completed the sale of its ABC-affiliated station WRTV in Indianapolis for $83 million, following the sale of its Fox-affiliated station WFTX in Fort Myers for $40 million, generating a total of $123 million in cash proceeds to be used for debt reduction and acquisition of ION-affiliated stations [1][2]. Group 1: Recent Transactions - The sale of WRTV to Circle City Broadcasting was finalized for $83 million [1]. - The sale of WFTX to Sun Broadcasting was completed for $40 million, contributing to a total cash inflow of $123 million from both transactions [2]. - The aggregate purchase price for the INYO stations, which Scripps plans to acquire, is approximately $54 million, pending the timing of the deal closure [3]. Group 2: Strategic Implications - The proceeds from the sales will be utilized for debt paydown and to facilitate the purchase of 23 ION-affiliated stations, which were divested to comply with FCC ownership rules [2][3]. - Ownership of the INYO stations is expected to be immediately accretive to Scripps Networks division segment profit and margin, enhancing coordination with other Scripps stations for new local programming opportunities [3]. - Scripps has also entered into an agreement to swap stations in five markets with Gray Television, aimed at strengthening its competitive position in key Mountain West markets, pending regulatory approval [4].

Core Insights - Edible Garden AG Incorporated is strategically evolving from its core controlled environment agriculture (CEA) platform into a broader consumer packaged goods (CPG) business, focusing on higher-margin opportunities [5][7][20] - The company is expanding its distribution network and product offerings, particularly in the ready-to-drink (RTD) category, which is projected to grow significantly in the coming years [7][20] Financial & Operating Highlights - For the three months ended December 31, 2025, revenue was approximately $4.1 million, a slight increase from $3.9 million in the same period in 2024, supported by new account launches [9] - The cost of goods sold for the same period was approximately $5.3 million, up from $3.8 million in 2024, primarily due to onboarding new customers during a peak season [10] - Gross profit for the quarter was approximately $(1.2) million, compared to $0.0 million in 2024, reflecting a gross margin of approximately -29% [11] - Selling, general and administrative expenses increased to approximately $4.6 million for the quarter, up from $2.6 million in 2024, driven by investments in personnel and infrastructure [12] Year-End Financial Overview - For the year ended December 31, 2025, revenue was approximately $12.8 million, down from $13.9 million in 2024, due to a strategic shift away from lower-margin products [13] - The cost of goods sold for the year was $13.0 million, an increase of 12.7% from $11.5 million in 2024, driven by elevated procurement and logistics costs [14] - Gross profit for the year was $(0.2) million, a decrease of $2.5 million from $2.3 million in 2024, with a gross margin decline to (1.6%) from 16.7% [15] - Selling, general and administrative expenses rose by 34.6% to $15.6 million for the year, compared to $11.6 million in 2024, with significant contributions from depreciation, rent, and professional fees [16] Strategic Initiatives - The company is focusing on expanding into the RTD category, leveraging its sustainable manufacturing infrastructure and established retail relationships [7][20] - A strategic partnership with Tetra Pak is planned to enhance processing capabilities for RTD products, aiming to meet growing consumer demand for clean-label nutrition [7] - The global RTD market is valued at approximately $842.5 billion in 2025 and is projected to reach roughly $1.26 trillion by 2033, presenting a significant growth opportunity for the company [7]

Core Insights - Banzai International, Inc. reported a significant revenue growth of 169% for the full year 2025, reaching $12.2 million, and a 116% increase in Q4 2025 revenue compared to Q4 2024, amounting to $2.8 million [1][2][3] Financial Performance - Q4 2025 gross profit was $2.3 million, reflecting a 148% increase from Q4 2024, with a gross margin of 81.9%, up from 71.3% in the same quarter of the previous year [2][11] - For FY 2025, gross profit reached $10.0 million, a 221% increase from FY 2024, with a gross margin of 82.0%, compared to 68.6% in FY 2024 [2][14] - The net loss for Q4 2025 improved to ($5.0) million from ($7.9) million in Q4 2024, while the full year net loss improved by 29% to ($22.5) million from ($31.5) million in FY 2024 [2][15] Strategic Acquisitions - The company signed a Letter of Intent to acquire the assets of ConnectAndSell, which had an unaudited revenue of $14.7 million in FY 2025 and gross margins of 86%, which is expected to more than double Banzai's annual revenue and enhance its AI platform capabilities [2][7] - Banzai also acquired the assets of Superblocks, an agentic AI platform, to further develop its marketing technology offerings [7] Customer Base and Market Position - Banzai's customer base includes over 150,000 total customers as of December 31, 2025, indicating strong market penetration and customer engagement [2][4] - The company is focusing on mid-market and enterprise customers, which has contributed to its revenue growth and improved gross margins [4] Balance Sheet Improvements - The company reduced its debt by $3.8 million compared to the previous quarter, with total debt repayments of $32.7 million since September 2024 [2][5] - Stockholders' equity increased to $8.1 million as of December 31, 2025, an increase of $10.8 million compared to the previous year [2][6] Future Outlook - Banzai aims to deepen relationships with enterprise and mid-market customers while continuing to invest in AI capabilities to enhance customer value [8][9] - The company maintains an active pipeline of potential acquisition opportunities across key industries, leveraging its AI platform for strategic operational acceleration [9]

Core Viewpoint - dLocal Limited, a financial technology company, will release its financial results for the first fiscal quarter ended March 31, 2026, on May 14, 2026, after market close [1]. Group 1: Financial Results Announcement - The financial results will be announced on May 14, 2026, after market close [1]. - A conference call and video webcast will be hosted on the same day at 6:00 p.m. Eastern Time [1]. Group 2: Conference Call Details - Investors can pre-register for the conference call to obtain the dial-in number and passcode [2]. - The live conference call will also be accessible via audio webcast on the company's investor relations website [2]. - An archive of the webcast will be available for one year following the conclusion of the conference call [2]. Group 3: Company Overview - dLocal connects global enterprise merchants with billions of consumers in emerging markets across APAC, the Middle East, Latin America, and Africa [3]. - The "One dLocal" concept allows global companies to manage payments, payouts, and fund settlements through a single API, platform, and contract [3].

Core Viewpoint - Trust Stamp has made significant progress in Q1 2026 by optimizing expenditures and focusing on revenue-generating projects, leading to multiple new contracts and partnerships across various sectors and regions [1][3]. Group 1: Revenue Generation and Contracts - The company received a Purchase Order for its Irreversibly Transformed Identity Token from a telecommunications company serving hundreds of millions of subscribers across Africa and the Middle East, projected to generate seven-figure annual recurring revenue (ARR) [1]. - Trust Stamp entered its first revenue-generating contract in Japan with Digital Platformer, marking a strategic entry into the Japanese market [1]. - A security guard authentication technology is set to roll out in fifty locations in the US, indicating growth potential in the workforce management sector [1]. - An agreement with IDirect, a long-standing player in the US security industry, is expected to lead to millions of monthly transactions, with potential for a seven-figure ARR engagement [1]. - The company has a successful revenue-generating implementation in the healthcare sector and anticipates scaling its technology further in this vertical [1]. Group 2: Strategic Initiatives and Partnerships - Trust Stamp is exploring opportunities in Nigeria's digital economy, aiming for a first government engagement in 2026 [1]. - Participation in the European Union's IPCEI program for semiconductor technologies could lead to significant public and private funding opportunities [1]. - The onboarding of 100 financial institutions with over $350 billion in assets via FIS has increased the total number of customers implementing the Orchestration Layer to 114 [1]. Group 3: Technology Development and Acquisitions - Continued development of the Wallet of Wallets (WoW) is underway, with plans to launch once legislative clarity is achieved [2]. - The acquisition of lexverify.com enhances the company's capabilities in AI-automated compliance and is expected to generate revenue within the next 12 months [2]. - A 50% ownership interest in thecyberfish.com provides access to advanced cyber resilience training and simulations, with plans for expansion [2]. Group 4: Market Expansion and Intellectual Property - Senior Advisors have been appointed in key markets, structured with revenue-based compensation aiming for seven-figure ARR [2]. - The company has extended its intellectual property portfolio with multiple patents and trademark applications related to authentication technologies [2].

Core Insights - Trust Stamp has onboarded 100 financial institutions with over $350 billion in assets through FIS, increasing the total number of customers to 114 [1] - Transaction starts for FIS-related institutions rose by 247% year-over-year, while customer completion rates increased by over 30% [1] Financial Performance - Net recognized revenue for the year ended December 31, 2025, was $3.14 million, a 2% increase from $3.08 million in 2024, primarily due to an amendment in a contract with an S&P 500 bank [5] - Total operating expenses decreased by 13% to $10.80 million in 2025 from $12.45 million in 2024 [5] - Comprehensive loss for 2025 was $8.33 million, a 31.8% reduction from $12.5 million in 2024, with basic and diluted net loss per share at $2.67 compared to $11.36 in 2024 [5] - Cash and cash equivalents as of December 31, 2025, were $6.04 million, contributing to total current assets of $7.48 million [5] - Total liabilities decreased to $2.35 million as of December 31, 2025, from $5.41 million in 2024, reflecting the repayment of secured borrowing [5] - Shareholder equity increased by 188% to $8.73 million as of December 31, 2025, from $3.03 million in 2024 [5] Company Overview - Trust Stamp is a global provider of AI-powered services across various sectors, including banking, finance, and healthcare, focusing on reducing fraud and enhancing operational efficiency [2] - The company operates with a diverse team from 22 nationalities across eight countries [3]

Core Viewpoint - BioAtla, Inc. is implementing a 50-for-1 share consolidation to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement of $1.00, effective April 6, 2026 [1][2]. Company Actions - The share consolidation will convert every fifty shares of common stock into one share, with no fractional shares issued; stockholders entitled to fractional shares will receive cash equivalent [4]. - The consolidation was approved by stockholders at a special meeting on March 23, 2026, as part of a merger agreement with its wholly-owned subsidiary, BA Merger Sub, Inc. [3]. Impact on Stock and Options - Following the consolidation, the number of shares available under the company's equity incentive plan and employee stock purchase plan will be proportionately reduced, and adjustments will be made to the exercise prices and number of shares for outstanding stock options and warrants [5]. Stockholder Information - Stockholders holding shares electronically will not need to take action to receive post-consolidation shares, while those with shares through brokers will have their positions automatically adjusted [6]. Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, with a robust pipeline including ADCs and T cell engagers [7]. - The company has over 780 active patent matters, with more than 500 issued patents, covering its CAB platform technology and products [7]. Clinical Pipeline - BioAtla's clinical pipeline includes Ozuriftamab vedotin (CAB-ROR2-ADC) in Phase 3 for OPSCC and Mecbotamab vedotin (CAB-AXL-ADC) in Phase 2 for multiple solid tumor indications [8][13]. - The company is also developing BA3182, a bispecific T cell engager antibody, currently in Phase 1 for advanced adenocarcinoma [10]. Market Opportunity - Ozuriftamab vedotin targets a market opportunity exceeding $7 billion worldwide, particularly for HPV+ cancers, and has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck [11].

Core Insights - Rinzimetostat 400 mg once daily has been selected as the recommended Phase 3 dose (RP3D) in combination with darolutamide for the Himalayas-1 global Phase 3 registrational trial in post-abiraterone metastatic castration-resistant prostate cancer (mCRPC), with initiation expected in the first half of 2026 [1][4][10] - The 5-month radiographic progression-free survival (rPFS) rate of 84% is consistent with competitor PRC2 inhibitors and significantly better than standard care therapies in mCRPC [1][16] - Rinzimetostat demonstrates a highly differentiated safety profile with a lower frequency and severity of adverse events compared to competitor regimens, with most adverse events being Grade 1 or 2 [1][6][10] Company Updates - ORIC Pharmaceuticals, Inc. is focused on developing treatments that address mechanisms of therapeutic resistance in oncology [3][17] - The company plans to host a conference call and webcast to discuss the rinzimetostat program update [2][15] - The Himalayas-1 trial will enroll approximately 600 patients from over 250 sites in more than 20 countries, randomized to receive either the RP3D of rinzimetostat or physician's choice of an AR inhibitor or chemotherapy [10] Clinical Trial Details - The Phase 1b trial of rinzimetostat in combination with darolutamide involved patients who had previously received a median of two lines of therapy, including abiraterone [5][14] - The recommended Phase 3 dose was selected based on a comprehensive exposure-response analysis, which indicated that the 400 mg dose provided comparable efficacy with a better safety profile than the 600 mg dose [7][8] - Early efficacy data show promising results, with landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, and significant PSA response rates [10][13][16] Market Potential - The annual incidence of mCRPC patients previously treated with abiraterone in the US is approximately 17,000, with an estimated addressable market exceeding $3.5 billion and a total global addressable market of $7 billion [11]

Core Insights - TOMI Environmental Solutions, Inc. reported financial results for the year ended December 31, 2025, highlighting strategic initiatives aimed at long-term growth [1] Financial Results - Sales for 2025 were $5,636,000, a decrease from $7,739,000 in 2024, attributed to customers deferring capital expenditures due to economic uncertainties [5] - Gross profit margin remained strong at approximately 55%, indicating operational efficiency [5] - Operating loss was ($3,854,000) for 2025, compared to a loss of ($4,105,000) in 2024 [5] - Net loss for 2025 was $(3,749,000) or $(0.19) per share, an improvement from a net loss of $(4,477,000) or $(0.22) per share in 2024 [5][25] - Cash and cash equivalents as of December 31, 2025, were $88,000, with working capital of $1.0 million [8] Recent Business Highlights - The company strengthened government relationships, notably being selected by NASA for a biosecurity operation [5] - New customer acquisitions included global CDMOs and prestigious university research groups [5] - Regulatory developments in the food market have expanded applications for SteraMist iHP, particularly in food safety [5] - International revenue increased to approximately 29% of total revenue, up from 21% in the previous year [5] Operational Efficiencies - Total operating expenses were reduced by approximately 10% in 2025 [5] - The company is exploring AI-related technologies to enhance operational efficiency [5] Product Innovation - Continued investment in R&D to expand SteraMist® applications across various sectors, resulting in a more comprehensive product portfolio [5] - SteraMist was recognized as the Disinfection and Decontamination Products Company of the Year 2025 by MedTech Outlook [5] Strategic Validation - A USDA study confirmed the efficacy of BIT against deformed wing virus for agricultural biosecurity in honeybees [5] Liquidity and Capital Access - The company completed a $535,000 convertible note financing to support growth initiatives [8] - An equity line of credit allows the company to sell up to $20,000,000 in common stock over a 24-month period [8] Market Opportunities - The food safety market is projected to grow from $28 million in 2025 to $31 million in 2026 [9] - The global medical device sterilization market is valued at $5.29 billion [10] - The company aims to penetrate the biofuel market and enhance domestic energy security [10] Looking Ahead - The company enters 2026 with strong operational momentum and a sales pipeline valued at $16 million for integration projects and $20 million for SteraMist iHP [11] - Focus on clean manufacturing, AI-enabled automation, and biosecurity to drive sustainable long-term growth [11]